FDA Evaluates Illumina GA, 454 for Vaccine QC; Looks to Implement Method for Polio Vaccine | GenomeWeb

By Monica Heger

Scientists at the US Food and Drug
Administration have begun to explore next-gen sequencing's potential for quality control in the manufacture of vaccines and have so far tested the ability of Roche's 454 GS FLX and the Illumina Genome Analyzer to identify pathogenic mutations in live attenuated polio vaccine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.